LUNAC Therapeutics is a spin out from the University of Leeds, UK and is pursuing the discovery of next generation oral anticoagulant therapies with a reduced risk of causing bleeding compared to current treatments.
The business is founded on IP generated by Professor Helen Philippou (Professor of Translational Medicine in the Faculty of Medicine and Health at the University of Leeds) and Dr Richard Foster (Associate Professor at the University of Leeds), built on a decade of academic research into FXIIa in association with some of the world’s leading supporters of scientific and medical research, including the Wellcome Trust, British Heart Foundation and the UK’s Medical Research Council.
Company Details
- Address
- Leeds, Gb
- Industry
- Research
- Website
- http://www.lunactherapeutics.com
- Keywords
- BD (Tissuemed Ltd).
- HQ
- Leeds
Lunac Therapeutics Questions
Lunac Therapeutics's website is http://www.lunactherapeutics.com
Lunac Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/lunac-therapeutics
Lunac Therapeutics's industry is
Research
Lunac Therapeutics's top competitors are
V&v Health Innovations.ltd,
Promatica Health & Care,
Leeds Digital,
Biostress,
Leeds Digital Health,
Videregen Limited,
The Yorkshire Swim Works,
Neotherix Ltd,
Bd (Tissuemed Ltd),
Avacta Therapeutics.
Lunac Therapeutics's categories are Research
